Mood stabilisers and risk of stroke in bipolar disorder

Pao-Huan Chen, Shang-Ying Tsai, Chun-Hung Pan, Chi-Kang Chang, Sheng-Shiang Su, Chiao-Chicy Chen, Chian-Jue Kuo

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Research on the risk of stroke following the use of mood stabilisers specific to patients with bipolar disorder is limited.AimsIn this study, we investigated the risk of stroke following the exposure to mood stabilisers in patients with bipolar disorder.

METHOD: Data for this nationwide population-based study were derived from the Taiwan National Health Insurance Research Database. Among a retrospective cohort of patients with bipolar disorder (n = 19 433), 609 new-onset cases of stroke were identified from 1999 to 2012. A case-crossover study design utilising 14-day windows was applied to assess the acute exposure effect of individual mood stabilisers on the risk of ischaemic, haemorrhagic and other types of stroke in patients with bipolar disorder.

RESULTS: Mood stabilisers as a group were significantly associated with the increased risk of stroke in patients with bipolar disorder (adjusted risk ratio, 1.26; P = 0.041). Among individual mood stabilisers, acute exposure to carbamazepine had the highest risk of stroke (adjusted risk ratio, 1.68; P = 0.018), particularly the ischaemic type (adjusted risk ratio, 1.81; P = 0.037). In addition, acute exposure to valproic acid elevated the risk of haemorrhagic stroke (adjusted risk ratio, 1.76; P = 0.022). In contrast, acute exposure to lithium and lamotrigine did not significantly increase the risk of any type of stroke.

CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalBritish Journal of Psychiatry
DOIs
Publication statusPublished - 2019

Fingerprint

Bipolar Disorder
Stroke
Odds Ratio
Carbamazepine
Valproic Acid
Lithium
Cross-Over Studies
National Health Programs
Taiwan
Research
Databases
Population

Cite this

Mood stabilisers and risk of stroke in bipolar disorder. / Chen, Pao-Huan; Tsai, Shang-Ying; Pan, Chun-Hung; Chang, Chi-Kang; Su, Sheng-Shiang; Chen, Chiao-Chicy; Kuo, Chian-Jue.

In: British Journal of Psychiatry, 2019, p. 1-6.

Research output: Contribution to journalArticle

Chen, Pao-Huan ; Tsai, Shang-Ying ; Pan, Chun-Hung ; Chang, Chi-Kang ; Su, Sheng-Shiang ; Chen, Chiao-Chicy ; Kuo, Chian-Jue. / Mood stabilisers and risk of stroke in bipolar disorder. In: British Journal of Psychiatry. 2019 ; pp. 1-6.
@article{9032e3d0348e4011986e888f2c8d9c21,
title = "Mood stabilisers and risk of stroke in bipolar disorder",
abstract = "BACKGROUND: Research on the risk of stroke following the use of mood stabilisers specific to patients with bipolar disorder is limited.AimsIn this study, we investigated the risk of stroke following the exposure to mood stabilisers in patients with bipolar disorder.METHOD: Data for this nationwide population-based study were derived from the Taiwan National Health Insurance Research Database. Among a retrospective cohort of patients with bipolar disorder (n = 19 433), 609 new-onset cases of stroke were identified from 1999 to 2012. A case-crossover study design utilising 14-day windows was applied to assess the acute exposure effect of individual mood stabilisers on the risk of ischaemic, haemorrhagic and other types of stroke in patients with bipolar disorder.RESULTS: Mood stabilisers as a group were significantly associated with the increased risk of stroke in patients with bipolar disorder (adjusted risk ratio, 1.26; P = 0.041). Among individual mood stabilisers, acute exposure to carbamazepine had the highest risk of stroke (adjusted risk ratio, 1.68; P = 0.018), particularly the ischaemic type (adjusted risk ratio, 1.81; P = 0.037). In addition, acute exposure to valproic acid elevated the risk of haemorrhagic stroke (adjusted risk ratio, 1.76; P = 0.022). In contrast, acute exposure to lithium and lamotrigine did not significantly increase the risk of any type of stroke.CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone.",
author = "Pao-Huan Chen and Shang-Ying Tsai and Chun-Hung Pan and Chi-Kang Chang and Sheng-Shiang Su and Chiao-Chicy Chen and Chian-Jue Kuo",
year = "2019",
doi = "10.1192/bjp.2018.203",
language = "English",
pages = "1--6",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",

}

TY - JOUR

T1 - Mood stabilisers and risk of stroke in bipolar disorder

AU - Chen, Pao-Huan

AU - Tsai, Shang-Ying

AU - Pan, Chun-Hung

AU - Chang, Chi-Kang

AU - Su, Sheng-Shiang

AU - Chen, Chiao-Chicy

AU - Kuo, Chian-Jue

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Research on the risk of stroke following the use of mood stabilisers specific to patients with bipolar disorder is limited.AimsIn this study, we investigated the risk of stroke following the exposure to mood stabilisers in patients with bipolar disorder.METHOD: Data for this nationwide population-based study were derived from the Taiwan National Health Insurance Research Database. Among a retrospective cohort of patients with bipolar disorder (n = 19 433), 609 new-onset cases of stroke were identified from 1999 to 2012. A case-crossover study design utilising 14-day windows was applied to assess the acute exposure effect of individual mood stabilisers on the risk of ischaemic, haemorrhagic and other types of stroke in patients with bipolar disorder.RESULTS: Mood stabilisers as a group were significantly associated with the increased risk of stroke in patients with bipolar disorder (adjusted risk ratio, 1.26; P = 0.041). Among individual mood stabilisers, acute exposure to carbamazepine had the highest risk of stroke (adjusted risk ratio, 1.68; P = 0.018), particularly the ischaemic type (adjusted risk ratio, 1.81; P = 0.037). In addition, acute exposure to valproic acid elevated the risk of haemorrhagic stroke (adjusted risk ratio, 1.76; P = 0.022). In contrast, acute exposure to lithium and lamotrigine did not significantly increase the risk of any type of stroke.CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone.

AB - BACKGROUND: Research on the risk of stroke following the use of mood stabilisers specific to patients with bipolar disorder is limited.AimsIn this study, we investigated the risk of stroke following the exposure to mood stabilisers in patients with bipolar disorder.METHOD: Data for this nationwide population-based study were derived from the Taiwan National Health Insurance Research Database. Among a retrospective cohort of patients with bipolar disorder (n = 19 433), 609 new-onset cases of stroke were identified from 1999 to 2012. A case-crossover study design utilising 14-day windows was applied to assess the acute exposure effect of individual mood stabilisers on the risk of ischaemic, haemorrhagic and other types of stroke in patients with bipolar disorder.RESULTS: Mood stabilisers as a group were significantly associated with the increased risk of stroke in patients with bipolar disorder (adjusted risk ratio, 1.26; P = 0.041). Among individual mood stabilisers, acute exposure to carbamazepine had the highest risk of stroke (adjusted risk ratio, 1.68; P = 0.018), particularly the ischaemic type (adjusted risk ratio, 1.81; P = 0.037). In addition, acute exposure to valproic acid elevated the risk of haemorrhagic stroke (adjusted risk ratio, 1.76; P = 0.022). In contrast, acute exposure to lithium and lamotrigine did not significantly increase the risk of any type of stroke.CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone.

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85067254292&origin=resultslist&sort=plf-f&src=s&sid=f8cb2461295133d726f918c0aef69288&sot=autdocs&sdt=autdocs&sl=18&s=AU-ID%2836656683000%29&relpos=2&citeCnt=0&searchTerm=

U2 - 10.1192/bjp.2018.203

DO - 10.1192/bjp.2018.203

M3 - Article

C2 - 30295208

SP - 1

EP - 6

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

ER -